Genentech's Sefaxersen Reduces Proteinuria 43.1% Versus Placebo in Phase III IgA Nephropathy Trial

By Public Technologies
  • Genentech announced interim Phase III results showing investigational sefaxersen significantly reduced urinary protein versus placebo in adults with IgA nephropathy.
  • Results were presented at the American Society of Nephrology Kidney Week 2026 on Oct. 23.
  • Treatment effects were consistent across prespecified patient subgroups, with no new safety signals.
  • The IMAgINATION trial will continue evaluating kidney function over two years.
  • Sefaxersen is designed as a once-monthly injection for self-administration at home.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genentech Inc. published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.